咨询电话：15012456311
咨询电话：15012456311西格列汀适应症及前景：磷酸西格列汀片是*个批准用于治疗2型糖尿病的DPP-4抑制剂，可抑制β细胞凋亡，促进β细胞新生，增加2型糖尿病患者β细胞数量，明显降低患者血糖，并且对磺脲类药物失效的患者仍有显著的降糖作用。磷酸西格列汀片主要通过配合运动和饮食控制实现对2型糖尿病患者的血糖控制。
经上市后超过上千万余张处方的检验，西格列汀进一步显示出强有效的降糖疗效和优异的安全性，成为降糖药物中耀眼的新星。西格列汀的巨大成功也获得了医药科技界同仁的广泛赞誉，各种奖项接踵而至，其中zui值得一提的是2007年度的“爱迪生奖”和“盖伦奖”等殊荣。2009 3月21日，中国国家食品药品监督管理局已正式批准其捷诺维（磷酸西格列汀）在中国上市， 使之成为国内市场上*用于治疗2型糖尿病的（DPP-4）抑制剂。
深圳远扬化学技术有限公司提供西格列汀全套杂质，随货提供结构确认图谱，纯度高，稳定性好， （详情请点击本页标题下方“进入该公司展台” 查看我司信息）。
| Sitagliptin | (R)-3-ami-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one |
| Sitagliptin Impurity 1 | (R)-3-((tert-butoxycarbonyl)amino)-4-(3,4-difluorophenyl)butanoic acid |
| Sitagliptin Impurity 2 | (R)-3-((tert-butoxycarbonyl)amino)-4-(2,4-difluorophenyl)butanoic acid |
| Sitagliptin Impurity 3 | (R)-3-((tert-butoxycarbonyl)amino)-4-(2,5-difluorophenyl)butanoic acid |
| Sitagliptin Impurity 4 | (S)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoic acid |
| Sitagliptin Impurity 5 | (R)-methyl 3-((tert-butoxycarbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoate |
| Sitagliptin Impurity 6 | (R)-methyl 3-amino-4-(2,4,5-trifluorophenyl)butanoate |
| Sitagliptin Impurity 7 | (R)-3-amino-4-(3,4-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one |
| Sitagliptin Impurity 8 | (R)-3-amino-4-(2,4-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one |
| Sitagliptin Impurity 9 | (R)-3-amino-4-(2,5-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one |
| Sitagliptin Impurity 10 | (R)-3-((tert-butoxycarbonyl)amino)-4-(2,4,5-trifluorophenyl)butanoic acid |
| Sitagliptin Impurity 11 | (R)-tert-butyl (4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl)carbamate |
| Sitagliptin Impurity 12 | (S)-3-ami-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one |
| Sitagliptin Impurity 13 | 1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butane-1,3-dione |
| Sitagliptin Impurity 14 | (Z)-3-ami-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-2-en-1-one |
| Sitagliptin Impurity 15 | (R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid |
| Sitagliptin Impurity 16 | (E)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-2-en-1-one |
| Sitagliptin Impurity 17 | (E)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-3-en-1-one |
